An analysis of the future "Chinese-style" pharmacy industry development trends

The development stage of Chinese pharmacies is still in the 1990 era of the United States, highly dispersed, but this is also the pharmacy industry is facing a major development opportunity. The worst of the early single-product categories and small dispersions has passed, and the industry is now at an inflection point, recovering from the trough.
in the domestic large-scale drugstore chain has entered the general trend of integration of mergers and acquisitions, to the people's company, for example, the company in the next 3-5 years will intend to use capital strength through self-built mergers and acquisitions and other ways to continuously increase the intensity of regional stores, while the company will also seek to expand the country, the acquisition of leading drugstores around the country, to build South China, Central China, East China, North China and Northwest five annual sales of 1-2 billion yuan of large-scale marketing network. We still refer to the benchmark company CVS (West Vixens Pharmacy, the largest drugstore chain in the United States), after 1999 with the extension of the layout gradually advanced and the Internet gradually popularized, began to use the Internet to integrate related medical resources layout pharmacy version 2.0, a comprehensive user-centric platform ecology.1, mining the value of the entrance, the introduction of ExtraCareCard, so that most of the traffic to become active traffic
CVS is the first in the United States to launch membership card pharmacy, for its members to provide discount services and other proliferation services, personal drug purchase management, annual points exchange gifts, additional provision of multiple commodity ticket printing services, so far the company's membership card program has more than 70 million members. Data show that the former store sales of members accounted for more than 70% of sales, members on average each time than non-members to buy 85% more goods. Through the membership card program, the company can also count customers' personal shopping habits, form big data, do precision marketing and services, improve customer loyalty and stickiness.2, tap the value of the pharmacy platform to stick to users and cash out
CVS opened a one-minute rapid clinic to provide diagnosis, treatment of basic health problems, health checks, vaccinations, chronic disease monitoring and other services; The Specialty specialty shop is opened to complement the general pharmacy and one-minute clinic. The main service object is rare diseases and complex diseases, there are specialized doctors 24 hours to provide drug management and distribution services, customized counseling, patient education and management; The use of mobile Internet platform to carry out services, greatly enhance the user stickiness and customer unit price. In addition, CVS has entered the field of drug benefit management (PBM) through the acquisition of Ceremark to help customers choose cost-effective drug options and provide a full range of value-added services for health management.3, the market value in 20 years 30 times
company to maintain continuous expansion, layout of the entire industrial chain at the same time continue to enrich operational experience, to maintain performance and stock prices continue to rise, the market value of the listing in 20 years has increased about 30 times, in recent years to do the integration of the entire industrial chain PE is also relative to the S and P has been a premium rate.
chinese pharmacies have every potential to follow the example of the United States and develop a localized model and become a platform service provider for healthcare and daily life services. It is worth noting that with the help of the Internet and capital forces, China's large pharmacy chains may have a shorter time period to become platform service providers.A brief analysis of the future development trend of China's pharmacy industry has the following characteristics: 1, the industry space has become larger: "pharmacy OTC drug-based" into "pharmacy-wide class drugs
From the point of view of the point of sale, including hospitals, communities and pharmacies, the medical side is still the main body of drug sales. However, it can be expected that, as medicines separate, the 80 per cent share of the medical end may flow in part to retail pharmacies and e-commerce terminals in the future, which could eventually reach 80 per cent compared to other countries where medicines are available, which will create huge incremental space for pharmacy chains.2, the change of competition pattern, the strong are stronger: "highly dispersed" to
centralized" industry changes in addition to space expansion, the trend of centralization will become more and more obvious. At present, the pharmaceutical retail industry is highly dispersed, fierce competition, online pharmacies also give birth to a price war, these factors make small-scale pharmacies profitability decline, the industry will give birth to many mergers and acquisitions opportunities, listed drugstore chains with the help of capital strength is expected to be stronger, will fully enjoy the merger and acquisition feast.3, the industrial chain profit distribution increased, profitability is strong: "weak position" into a "strong position
China is a large generic drug country, the concentration of upstream industry is low, with the liberalization of drug prices, upstream drug companies will be more intense bidding, will be more and more dependent on terminal sales. In terms of end-share, prescription drugs will flow to retail terminals after the separation of medicines, so it can be expected that future sales across the pharmaceutical industry will be more dependent on pharmacy retail terminals. It can be seen that the pharmacy terminal in the future in the entire industrial chain will occupy a more important position, the status of the industrial chain will be greatly enhanced.4, model changes to shape the ecology: "pure retailers" into "platform service providers
China's pharmaceutical retail industry profit model is still relatively single, mainly concentrated in therapeutic drugs, the difference between purchase and sale. And the world's leading pharmaceutical retail pharmacies have highlighted their own platform value, to bring people experience is not only retailers, has become a platform for health care and daily life services. In the future, the shape of Chinese pharmacies will also become a platform-based service provider, itself is the traffic entrance, and then use their own terminal platform around customer demand unlimited extension of the profit model, for example: pharmacies can open clinics; Pharmacy itself to do basic medical care, can seek high-end medical resources docking; Pharmacies naturally have the advantage of doing slow disease management, can integrate inspection services, the use of medical examination centers, POCT, household equipment, etc. to complete some basic inspection work. Under the catalysis of the Internet, China's large-scale pharmacy chains have accelerated into the era of pharmacy 2.0. Now China's large pharmacies have begun to change from a simple drug retailer to a platform-based service provider, all of its user demand as the center, to offline stores as the basis, to the Internet as a means to increase products, services, inspection and other products, to create O2O's medical ecology, pharmacies are the most widely laid out and most convenient offline medical related institutions, the future will become a pharmaceutical complex to develop O2O services, will be the Internet medical standards. Note: The full text mainly refers to Henyep Securities (601377, stock bar) "from chain to platform, to meet the 2.0 era of pharmacies", Guotai Junan "chain drugstore special report - mergers and acquisitions integration of the new era opened" medical health x investment to take you to read the health care industry investment! (Hexun)